IGF-1 LR3 Research Hub — Long R3 Insulin-like Growth Factor Studies
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is an 83-amino-acid analog engineered with an N-terminal extension and an Arg-for-Glu substitution at position 3, dramatically extending its half-life by reducing IGFBP binding. This hub collects Ares Research's reference material on its mechanism, signalling and relationship to the GH/IGF-1 axis.
What this hub covers
- Long R3 structural modifications and reduced IGFBP affinity
- Extended plasma half-life vs native IGF-1
- IGF-1R activation, PI3K/Akt/mTOR and MAPK signalling
- Relationship to HGH and the somatotropic axis
- Reconstitution, storage and handling for research use
IGF-1 LR3 research articles
All research →IGF-1 LR3 Research Overview
A complete research overview of IGF-1 LR3 — a long-acting analogue of insulin-like growth factor 1. Covers mechanism of action, binding protein resistance, anabolic signaling, muscle cell research, and comparison to native IGF-1.
Read article →IGF-1 LR3 Benefits and Side Effects: A Research Guide
Published benefits, side effects, and mecasermin comparisons for IGF-1 LR3 — the binding-protein-resistant IGF-1 analog used in muscle and biotech research.
Read article →HGH and IGF-1: Understanding the Downstream Axis
Comprehensive research guide to the HGH/IGF-1 axis — hepatic IGF-1 production, IGFBPs 1–6, the ternary complex, PI3K/AKT/mTOR signalling, and the systemic vs local IGF-1 distinction.
Read article →HGH (Somatropin) Research Overview
Recombinant human growth hormone (somatropin) is a 191-amino acid single-chain polypeptide identical to pituitary-derived GH — the definitive reference compound for GH axis research, with the most extensive clinical evidence base of any GH-related intervention and a fully characterised receptor signalling mechanism spanning JAK2/STAT5, MAPK, and PI3K pathways.
Read article →HGH & Body Composition: Lean Mass, Fat Loss & Recovery Research
Growth hormone occupies a central position in body composition regulation — stimulating lipolysis in adipose tissue, promoting protein synthesis in muscle, and driving IGF-1–mediated anabolic effects throughout the body. This article examines the documented mechanisms and clinical evidence base behind HGH's effects on lean mass, fat mass, and recovery.
Read article →IGF-1 LR3 research FAQ
- What makes IGF-1 LR3 different from native IGF-1?
- LR3 carries a 13-amino-acid N-terminal extension and a substitution at position 3 (arginine for glutamic acid). Together these modifications reduce binding to IGFBPs, allowing more of the molecule to remain bioavailable and extending its plasma half-life from minutes to several hours in the published research models.
- Which signalling pathways does IGF-1 LR3 engage?
- Like native IGF-1, LR3 binds the IGF-1 receptor and activates the PI3K/Akt/mTOR and Ras/MAPK cascades, with downstream effects on protein synthesis, cellular proliferation and glucose handling that are widely characterised in the literature.
- How is IGF-1 LR3 related to HGH research?
- HGH (somatropin) exerts many of its downstream effects through hepatic IGF-1 induction. IGF-1 LR3 is studied as a way to investigate IGF-1 receptor activation directly, bypassing the GH receptor and pulsatile pituitary release. The HGH research hub covers the upstream axis in detail.
- How is IGF-1 LR3 typically prepared for research?
- Lyophilized IGF-1 LR3 is reconstituted with bacteriostatic water or acidified saline depending on the protocol, then stored refrigerated and used within the window described on the COA. Always confirm purity and concentration against the batch certificate before use.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.